Lineage Cell Therapeutics (LCTX) Operating Margin (2010 - 2026)

Lineage Cell Therapeutics' Operating Margin history runs 17 years deep, the most recent figure standing at 440.17% for Q1 2026.

• In Q1 2026, Operating Margin fell 708.0% year-over-year to 440.17%; the TTM figure through Mar 2026 stood at 255.14% (down 3204.0% YoY), while the FY2025 annual figure was 251.57%, down 2547.0% from the prior year.
• Operating Margin for Q1 2026 stood at 440.17%, down from 99.09% in the prior quarter.
• The five-year high for Operating Margin was 92.99% in Q2 2022, with the low at 715.37% in Q2 2025.
• The 5-year median for Operating Margin is 278.37% (2023), against an average of 291.9%.
• The sharpest annual moves came in 2022 and 2023: Operating Margin soared 168094 bps in 2022, then plunged 36297 bps in 2023.
• Lineage Cell Therapeutics' Operating Margin stood at 346.68% in 2022, then grew by 12 bps to 304.69% in 2023, then surged by 42 bps to 178.17% in 2024, then soared by 44 bps to 99.09% in 2025, then slumped by 344 bps to 440.17% in 2026.
• Business Quant data shows LCTX's Operating Margin at 440.17% in Q1 2026, 99.09% in Q4 2025, and 102.85% in Q3 2025.